[Cis-diammino-dichloro-platinum therapy of cancers; phase II therapeutic trial].
We have conducted a phase II trial of cisdiammino-dichloro platinum (CDDP) which demonstrates its remarkable activity in testis embryonic carcinoma, in ovary carcinoma and in epidermoid cancers, especially head and neck and uterus cervix carcinoma. Its toxicity in mainly digestive and renal. This compound is now indicated in combinations in the case of the above mentioned tumors.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000188:drug therapy; D002648:Child; D002675:Child, Preschool; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004064:Digestive System / Q000187:drug effects; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D004407:Dysgerminoma / Q000188:drug therapy; D007758:Ear, Inner / Q000187:drug effects; D005260:Female; D006258:Head and Neck Neoplasms / Q000188:drug therapy; D006801:Humans; D007668:Kidney / Q000187:drug effects; D008297:Male; D008545:Melanoma / Q000188:drug therapy; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*; D010051:Ovarian Neoplasms / Q000188:drug therapy; D012878:Skin Neoplasms / Q000188:drug therapy; D013724:Teratoma / Q000188:drug therapy; D013736:Testicular Neoplasms / Q000188:drug therapy; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy
D002945:Cisplatin
Chimiothérapie des cancers par le cis-diammino-dichloro platinum; essai thérapeutique phase II.